...I mean, why would Novartis specifically target the "Extremely rare disease and also probably has no money" demographic? Or do...
Anonymous asked:
...I mean, why would Novartis specifically target the "Extremely rare disease and also probably has no money" demographic? Or do you mean they were researching a cure for cancer or male-pattern baldness and accidentally stumbled onto a cure for something entirely unrelated?
I have no idea how Novartis, in this specific case, arrived at this specific medicine.
But pharmaceuticals, in general, is a wild gamble and then you take what you get.
Generally, small start-ups are the ones that stumble onto things, then they develop it up through the Xth round of testing when it makes sense for the major to buy it out and take over development